Drug intelligence / Profile preview

Ascabiol

Development stage: Unknown
Lead developer: FRiLAB
Modality: Small Molecules
Administration: Topical

Overview

**Ascabiol** is a topical fixed-dose ectoparasiticide marketed by FRiLAB for **common scabies** and **autumnal trombiculosis** caused by chigger mites. The FRiLAB formulation is a 125 mL lotion containing **benzyl benzoate 10 g/100 mL** and **sulfiram 2 g/100 mL**. It is applied to the skin as a scabicidal and acaricidal treatment intended to eliminate mite infestations. ([frilab.ch](https://frilab.ch/en/product/ascabiol/))

Brand names: Ascabiol
Other names: benzyl benzoate + sulfiram

Beyond the preview

Go deeper on Ascabiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascabiol.

Explore the full profile